UroGen Pharma (LTS:0XOD) 3-Year Revenue Growth Rate : -0.70% (As of Dec. 2024)

View and export this data going back to 2018. Start your Free Trial

What is UroGen Pharma 3-Year Revenue Growth Rate?

UroGen Pharma's Revenue per Share for the three months ended in Dec. 2024 was $0.42.

During the past 12 months, UroGen Pharma's average Revenue per Share Growth Rate was -26.50% per year. During the past 3 years, the average Revenue per Share Growth Rate was -0.70% per year. During the past 5 years, the average Revenue per Share Growth Rate was 246.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

During the past 10 years, the highest 3-Year average Revenue per Share Growth Rate of UroGen Pharma was 1313.10% per year. The lowest was -91.20% per year. And the median was 36.80% per year.

Competitive Comparison of UroGen Pharma's 3-Year Revenue Growth Rate

For the Biotechnology subindustry, UroGen Pharma's 3-Year Revenue Growth Rate, along with its competitors' market caps and 3-Year Revenue Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

UroGen Pharma's 3-Year Revenue Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, UroGen Pharma's 3-Year Revenue Growth Rate distribution charts can be found below:

* The bar in red indicates where UroGen Pharma's 3-Year Revenue Growth Rate falls into.

Save Embed

;

Save Embed

;

UroGen Pharma 3-Year Revenue Growth Rate Calculation

This is the 3-year average growth rate of Revenue per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

UroGen Pharma (LTS:0XOD) 3-Year Revenue Growth Rate Explanation

Revenue per Share is the amount of Revenue per outstanding share of the company's stock.

Revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top. Revenue per share growth rate is used in calculating Predictability Rank, companies with more consistent revenue and earnings growth are ranked high with predictability.

UroGen Pharma 3-Year Revenue Growth Rate Related Terms

Thank you for viewing the detailed overview of UroGen Pharma's 3-Year Revenue Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

UroGen Pharma Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » UroGen Pharma Ltd (LTS:0XOD) » Definitions » 3-Year Revenue Growth Rate

Comparable Companies

Traded in Other Exchanges

URGN:USA UR8:Germany

Address

400 Alexander Park Drive, 4th Floor, Princeton, NJ, USA, 08540

Website

https://www.urogen.com

UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.

UroGen Pharma Headlines

No Headlines